| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 09/20/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 08/14/2023 | 302.3% | HC Wainwright & Co. | $21 → $21 | Reiterates | Buy → Buy |
| 06/06/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 05/26/2023 | 359.77% | Oppenheimer | → $24 | Reiterates | Outperform → Outperform |
| 05/26/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 05/16/2023 | 359.77% | Oppenheimer | → $24 | Reiterates | → Outperform |
| 04/24/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/30/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/29/2023 | 129.89% | B. Riley Securities | → $12 | Reiterates | → Buy |
| 03/28/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 02/28/2023 | 302.3% | HC Wainwright & Co. | → $21 | Maintains | Buy |
| 01/03/2023 | 302.3% | HC Wainwright & Co. | $15 → $21 | Maintains | Buy |
| 11/15/2022 | 206.51% | Chardan Capital | $15 → $16 | Maintains | Buy |
| 11/01/2022 | 91.57% | B. Riley Securities | → $10 | Initiates Coverage On | → Buy |
| 08/12/2021 | 187.36% | HC Wainwright & Co. | $20 → $15 | Maintains | Buy |
| 06/28/2021 | 378.93% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 06/09/2021 | 187.36% | Chardan Capital | $11 → $15 | Maintains | Buy |
| 06/02/2021 | 283.14% | HC Wainwright & Co. | $8 → $20 | Maintains | Buy |
| 05/20/2021 | 110.73% | Chardan Capital | $10 → $11 | Maintains | Buy |
| 03/19/2021 | 53.26% | HC Wainwright & Co. | $6 → $8 | Maintains | Buy |
| 05/27/2020 | -23.37% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/30/2020 | 34.1% | HC Wainwright & Co. | → $7 | Downgrades | Buy → Neutral |
| 11/05/2019 | 34.1% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 10/24/2019 | 91.57% | Chardan Capital | → $10 | Initiates Coverage On | → Buy |
What is the target price for PDS Biotechnology (PDSB)?
The latest price target for PDS Biotechnology (NASDAQ: PDSB) was reported by HC Wainwright & Co. on September 27, 2023. The analyst firm set a price target for $21.00 expecting PDSB to rise to within 12 months (a possible 302.30% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PDS Biotechnology (PDSB)?
The latest analyst rating for PDS Biotechnology (NASDAQ: PDSB) was provided by HC Wainwright & Co., and PDS Biotechnology reiterated their buy rating.
When is the next analyst rating going to be posted or updated for PDS Biotechnology (PDSB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PDS Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PDS Biotechnology was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
Is the Analyst Rating PDS Biotechnology (PDSB) correct?
While ratings are subjective and will change, the latest PDS Biotechnology (PDSB) rating was a reiterated with a price target of $0.00 to $21.00. The current price PDS Biotechnology (PDSB) is trading at is $5.22, which is within the analyst's predicted range.